Table 2.

Women 50–59 years of age at trial entry: WHI Estrogen-Alone Trial outcomes, 13-year cumulative long-term follow-up (intervention phase + postintervention phase).

Outcome	Hazard ratio (95% CI) Women 50–59 years of age CEE versus placebo	P for interaction (trend by age) for all participants, 50–79 years
Coronary heart disease (primary trial endpoint)a	0.65 (95% CI, 0.44–0.96)†	0.12
Myocardial infarction	0.60 (95% CI, 0.39–0.91)†	0.007‡
Invasive breast cancer	0.76 (95% CI, 0.52–1.11)	0.70
All cancer types	0.80 (95% CI, 0.64–0.99)†	0.18
All-cause death	0.78 (95% CI, 0.59–1.03)	0.10
Global indexb	0.82 (95% CI, 0.68–0.98)†	0.01‡

^aCoronary heart disease: nonfatal myocardial infarction or coronary death.

^bGlobal index represents the first event for each participant from among the following: coronary heart disease, stroke, pulmonary embolism, invasive breast cancer, colorectal cancer, hip fracture, or death due to other causes.

^†95% confidence interval does not include 1.0.

^‡Statistically significant (95% CI) P for interaction (trend by age).

CEE: conjugated equine estrogens; CI: confidence interval; WHI: Women's Health Initiative.

Source for outcomes: [3].